Streetbeat News

Price Targets

SKWD

Skyward Specialty (NASDAQ:SKWD) has received mixed ratings from 5 analysts over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $48.2, reflecting a positive outlook. Analysts have raised their price targets and ratings, indicating confidence in the company's financial performance, which includes strong revenue growth, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 5:00 pm

IONQ

Benchmark analyst David Williams maintains a Buy rating on IonQ (NYSE:IONQ) but lowers the price target from $16 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:56 pm

LGND

Benchmark analyst Robert Wasserman maintains a Buy rating on Ligand Pharmaceuticals (NASDAQ:LGND) and raises the price target from $95 to $110.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:53 pm

LSXMA

Benchmark analyst Matthew Harrigan has reiterated a Buy rating on Liberty SiriusXM Group (NASDAQ:LSXMA) and maintained a price target of $54.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:51 pm

PLUG

RBC Capital analyst Chris Dendrinos maintains a Sector Perform rating on Plug Power (NASDAQ:PLUG) but lowers the price target from $3.5 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:43 pm

SLVM

RBC Capital analyst Matthew McKellar maintains a Sector Perform rating on Sylvamo (NYSE:SLVM) and raises the price target from $63 to $71.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:41 pm

MOS

RBC Capital analyst Andrew Wong has reiterated a Sector Perform rating on Mosaic (NYSE:MOS) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:38 pm

LXU

RBC Capital analyst Andrew Wong has reiterated an Outperform rating on LSB Industries (NYSE:LXU) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:37 pm

IIIV

Raymond James analyst John Davis maintains a Strong Buy rating on i3 Verticals (NASDAQ:IIIV) but lowers the price target from $31 to $28.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:34 pm

LEGN

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 4:33 pm